Moderna, Inc. (MRNA) Return on Equity (ROE): -43.12%
Is Moderna, Inc.’s return on equity (ROE) high or low?
Moderna, Inc.'s return on equity (ROE) of -43.12% is 17348% below its 5-year average of 0.25%, near the low end of its 5-year range (-34.03%–86.26%).
The return on equity (ROE) for Moderna, Inc. (MRNA) is -43.12% as of Wednesday, June 10, 2026. It is below its 12-month average by 32.09% (-32.64%).
MRNA Return on Equity (ROE) Chart
MRNA Average Return on Equity (ROE) Chart
MRNA Current vs Average Return on Equity (ROE) Chart
MRNA Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-43.12%
RETURN ON EQUITY (ROE) AVG TTM
-32.64%
RETURN ON EQUITY (ROE) AVG 3Y
-13.90%
RETURN ON EQUITY (ROE) AVG 5Y
0.25%
RETURN ON EQUITY (ROE) AVG 10Y
-13.40%
RETURN ON EQUITY (ROE) AVG 15Y
-13.40%
RETURN ON EQUITY (ROE) AVG 20Y
-13.40%
CURRENT VS TTM AVG
-32.09%
CURRENT VS 3Y AVG
-210.27%
CURRENT VS 5Y AVG
-17348.00%
CURRENT VS 10Y AVG
-221.79%
CURRENT VS 15Y AVG
-221.79%
CURRENT VS 20Y AVG
-221.79%
MRNA Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $18.40B | -43.12% | -32.64% | -13.90% | 0.25% |
| Hologic, Inc. (HOLX) | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| BioNTech SE (BNTX) | $21.81B | -6.79% | -4.55% | 10.63% | 21.70% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Waters Corporation (WAT) | $23.83B | 2.94% | 29.98% | 64.02% | 111.55% |
| Align Technology, Inc. (ALGN) | $12.56B | 10.36% | 10.54% | 10.84% | 19.93% |
| Baxter International Inc. (BAX) | $10.49B | -18.17% | -12.46% | -8.76% | -1.37% |
| Veeva Systems Inc. (VEEV) | $26.73B | 12.89% | 12.42% | 12.32% | 13.45% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -6.28% | -2.13% | 6.32% | 9.65% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 2.46% | -8.94% | -15.72% | 1.14% |
Return Analysis
ROE
-43.1%
ROA
-27.8%
Moderna, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Moderna, Inc. (MRNA)?
- The return on equity (ROE) for MRNA stock is -43.12%.
- Is Moderna, Inc.'s return on equity (ROE) high or low?
- Moderna, Inc.'s return on equity (ROE) of -43.12% is 17348% below its 5-year average of 0.25%, near the low end of its 5-year range (-34.03%–86.26%).
- What is the TTM average return on equity (ROE) for Moderna, Inc. (MRNA)?
- The TTM average return on equity (ROE) for MRNA stock is -32.64%.
- What is the 3Y average return on equity (ROE) for Moderna, Inc. (MRNA)?
- The 3Y average return on equity (ROE) for MRNA stock is -13.90%.
- What is the 5Y average return on equity (ROE) for Moderna, Inc. (MRNA)?
- The 5Y average return on equity (ROE) for MRNA stock is 0.25%.
- What is the 10Y average return on equity (ROE) for Moderna, Inc. (MRNA)?
- The 10Y average return on equity (ROE) for MRNA stock is -13.40%.
- What is the 15Y average return on equity (ROE) for Moderna, Inc. (MRNA)?
- The 15Y average return on equity (ROE) for MRNA stock is -13.40%.
- What is the 20Y average return on equity (ROE) for Moderna, Inc. (MRNA)?
- The 20Y average return on equity (ROE) for MRNA stock is -13.40%.
Moderna, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -32.62% |
| 2024-12-31 | -32.67% |
| 2023-12-31 | -34.03% |
| 2022-12-31 | 43.73% |
| 2021-12-31 | 86.26% |
| 2020-12-31 | -29.17% |
| 2019-12-31 | -43.75% |
| 2018-12-31 | -25.14% |
| 2017-12-31 | -40.93% |
| 2016-12-31 | -25.68% |
Related Metrics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel